title: Normal pregnancy outcome after first-trimester exposure to liraglutide in a woman with Type 2 diabetes.
abstract: BACKGROUND
  Data from animal studies suggest that glucagon-like peptide-1 analogues should not be used in pregnancy, but there have been no reports to date of their effects in human pregnancy. The aim of the present report was to describe a case of exposure to liraglutide during the first trimester of pregnancy in a patient with Type 2 diabetes mellitus.
  
  
  METHODS
  A 37-year-old woman with Type 2 diabetes mellitus who had been taking liraglutide for 2 years was admitted in the 13(th) week of gestation. Liraglutide was immediately discontinued and intensive insulin therapy instituted. The woman gave birth to a healthy child after completing an uneventful gestation period.
  
  
  CONCLUSIONS
  Although the present normal pregnancy outcome does not mean that glucagon-like peptide-1 analogues are safe to use in pregnancy, this report contributes to the limited knowledge regarding human exposure to these drugs during pregnancy in women with diabetes.
authors: Unit of Diabetology, 'Paolo Borsellino' Hospital, Marsala, Italy.
authors: D
authors: D
authors: Greco
mesh_terms: D000328:Adult; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D057915:Drug Substitution; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007328:Insulin / Q000627:therapeutic use; D000069450:Liraglutide / Q000009:adverse effects / Q000627:therapeutic use*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011261:Pregnancy Trimester, First / Q000097:blood / Q000187:drug effects; D011254:Pregnancy in Diabetics / Q000188:drug therapy*
chemical_list: D007328:Insulin; D000069450:Liraglutide